Novartis secures FDA RMAT designation for Kymriah to treat follicular lymphoma
Kymriah has been previously approved for pediatric and young adult acute lymphoblastic leukemia (ALL), and adult diffuse large…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Apr 20
Kymriah has been previously approved for pediatric and young adult acute lymphoblastic leukemia (ALL), and adult diffuse large…
23 Apr 20
BioNTech and Pfizer have joined forces to develop BNT162, the vaccine that has potential to prevent the COVID-19…
13 Apr 20
NF1 is a rare and debilitating genetic condition, where 30-50% of patients with NF1 experience PN tumours growing…
09 Apr 20
BRAFTOVI plus cetuximab is an FDA approved regimen indicated for adults with previously treated metastatic CRC with a…
08 Apr 20
Merck’s supplemental biologics license application (sBLA) for KEYTRUDA has been acepted by FDA as monotherapy for patients with…
06 Apr 20
Rybelsus, which is currently being reviewed by regulatory agencies, including the Japanese Pharmaceuticals and Medical Devices Agency
02 Apr 20
FDA advises consumers, patients and health care professionals to withdraw Ranitidine, following the latest studies demonstrating risk to…
31 Mar 20
Taltz is a monoclonal antibody designed to selectively bind with interleukin 17A (IL-17A) and inhibit its interaction with…
31 Mar 20
Imfinzi is the only available immunotherapy that shows survival benefit in combination with etoposide and a choice of…
23 Mar 20
Health Canada approved VOCABRIA (cabotegravir) for short-term treatment, along with CABENUVA (cabotegravir and rilpivirine extended-release)